March 1, 2002Arthritis & Rheumatism

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trial

View Full Paper

Ask AI

Bookmark

Abstract

In patients with persistently active RA, the combination of anakinra and MTX was safe and well tolerated and provided significantly greater clinical benefit than MTX alone.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cohen et al. (2002) studied this question.

synapsesocial.com/papers/69d8c097d2f7327e70ae42a4 https://doi.org/10.1002/art.10141

View Full Paper

Ask AI

Bookmark

Abstract

In patients with persistently active RA, the combination of anakinra and MTX was safe and well tolerated and provided significantly greater clinical benefit than MTX alone.

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trial

Abstract

Discussion

Cite This Study

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading